C. Mascaux
Research Subjects
Research Interests
C. Mascaux has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
A. Haller
6 shared publicationsM Paesmans
Data Centre, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, B-1000 Brussels, Belgium
6 shared publicationsT Berghmans
Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, B-1000 Brussels, Belgium
6 shared publicationsV. Ninane
Service de Pneumologie, CHU Saint-Pierre
6 shared publicationsJ P Sculier
5 shared publicationsA. Burny
4 shared publications
Latest Publications
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , 7007
Use of a three-microRNA signature to discriminate prognostic groups in early-stage NSCLC patients in the IFCT-0002 trial.
7007 Background: No survival differences was observed between any arms in the 528 early stage NSCLC randomized patients of the IFCT-0002 phase III trial comparing two chemotherapy timing, all pre- vs. peri-operative, and two regimens, CDDP-Gem vs. CBDCA-Pac (V. Westeel, ASCO 2009). We hypothesized that microRNA (miRNA) expression profile could discriminate prognostic groups in these patients. Methods: Total RNA was extracted from 277 paraffin-embedded surgical macrodissected specimens. Expression of 17 miRNAs was successfully analyzed by Taqman qRT-PCR in 276 (99%) samples. Multivariate analysis with Cox model for overall survival (OS) was validated with a two-step bootstrap resampling analysis. Results: Low miR210 (under median) miR21, and miR15a, (under first quartile) expression significantly predicted a better survival when adjusted for stage and number of administered cycles, the two clinical variables influencing OS in multivariate analysis. A model including the three miRNAs discriminates three prognostic groups: Group 1: patients with the three miRNAs under the defined cut-off (n=129), Group 2: among the remaining patients, patients with miR21 under Q1, independently of the status of the two other miRNAs (n=82), and Group 3: all remaining patients (n=65). In univariate analysis, Group 1 showed the best OS (> 83 months), Group 2 intermediate OS (66 months), and Group 3 the worse OS (36 months, p=0.001, log-rank test). Adjusted HRs for OS with Group 3 as reference were 0.445, 95%CI [0.290-0.682], p=0.0002 and 0.632, 95%CI [0.406-0.986], p=0.043 for Group 1 and 2, respectively. Harrell’s concordance index of 0.83, 95%CI [0.67-0.95] showed a good predictive accuracy. A first bootstrap with 300 random resampling showed the stability of the miR model which significantly predicted OS in 260 samples (86.7%). The reproducibility of the model was confirmed by a second similar bootstrap procedure, the c-indexes of the created models ranging from 0.74 to 0.85. Conclusions: A miRNA model associating mIR15a, mIR21, and mIR210, accurately discriminates three prognostic groups in early-stage NSCLC patients treated by perioperative chemotherapy.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , 7007
Use of a three-microRNA signature to discriminate prognostic groups in early-stage NSCLC patients in the IFCT-0002 trial.
7007 Background: No survival differences was observed between any arms in the 528 early stage NSCLC randomized patients of the IFCT-0002 phase III trial comparing two chemotherapy timing, all pre- vs. peri-operative, and two regimens, CDDP-Gem vs. CBDCA-Pac (V. Westeel, ASCO 2009). We hypothesized that microRNA (miRNA) expression profile could discriminate prognostic groups in these patients. Methods: Total RNA was extracted from 277 paraffin-embedded surgical macrodissected specimens. Expression of 17 miRNAs was successfully analyzed by Taqman qRT-PCR in 276 (99%) samples. Multivariate analysis with Cox model for overall survival (OS) was validated with a two-step bootstrap resampling analysis. Results: Low miR210 (under median) miR21, and miR15a, (under first quartile) expression significantly predicted a better survival when adjusted for stage and number of administered cycles, the two clinical variables influencing OS in multivariate analysis. A model including the three miRNAs discriminates three prognostic groups: Group 1: patients with the three miRNAs under the defined cut-off (n=129), Group 2: among the remaining patients, patients with miR21 under Q1, independently of the status of the two other miRNAs (n=82), and Group 3: all remaining patients (n=65). In univariate analysis, Group 1 showed the best OS (> 83 months), Group 2 intermediate OS (66 months), and Group 3 the worse OS (36 months, p=0.001, log-rank test). Adjusted HRs for OS with Group 3 as reference were 0.445, 95%CI [0.290-0.682], p=0.0002 and 0.632, 95%CI [0.406-0.986], p=0.043 for Group 1 and 2, respectively. Harrell’s concordance index of 0.83, 95%CI [0.67-0.95] showed a good predictive accuracy. A first bootstrap with 300 random resampling showed the stability of the miR model which significantly predicted OS in 260 samples (86.7%). The reproducibility of the model was confirmed by a second similar bootstrap procedure, the c-indexes of the created models ranging from 0.74 to 0.85. Conclusions: A miRNA model associating mIR15a, mIR21, and mIR210, accurately discriminates three prognostic groups in early-stage NSCLC patients treated by perioperative chemotherapy.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 10575
Gene expression differences in current versus former smokers lung squamous preneoplasia.
10575 Background: The study of the molecular biology of the lung carcinogenesis would help finding biomarkers for early diagnosis and targets for chemoprevention. The present study aim to characterize genomic profiles between current and formers smokers in lung squamous carcinogenesis. Methods: 122 bronchial biopsies (67/55 from current/former smokers) at successive stages of lung squamous carcinogenesis (normal, hyperplasia, metaplasia, mild, moderate and severe dysplasia, carcinoma in situ and invasive carcinoma) obtained by fluorescence bronchoscopy in 74 high risk individuals (40/34 current/former smokers) were analyzed by gene expression microarrays (Mascaux, J Thorac Oncol 2009 4(9) S282). Results: 740 genes were significantly differentially expressed (FDR 0.05) between biopsies from current versus former smokers in bronchial pre-invasive lesions. The most significantly associated pathways was metabolism of xenobiotic by cytochrome CP450 eg CYP1A1, CYP2A6, ALDH1L1, but genes related to cancer pathways were also found, ie metallopeptidases, IGF binding proteins, cell growth and proliferation (ie EGF), or apoptosis (ie survivin). Our findings in lung preneoplasia were consistent by gene set enrichement analyses. (GSEA) with data previously reported on normal bronchial epithelial cells (Spira, PNAS 2004 101(27) 10143). Association between gene expression differences observed between the early steps of lung carcinogenesis in our study and between current and former smokers in normal bronchial epithelial cells in Spira study were analysed by GSEA. Some associations were observed: genes down-regulated in current smokers were also down-regulated in transition to squamous metaplasia including cancer genes like eg BCL2, FGF2, AKT3 and eicosanoid signaling eg PTGDR, PLA2G5. Conclusions: Genes discriminating current and former smokers during lung carcinogenesis include genes involved in metabolism of xenobiotic by cytochrome CP450, cell proliferation and apoptosis. Cigarette smoke exposure effects on normal epithelial cells and on preneoplasia from different data sets are related. Genes related to current smoking like eicosanoid signaling genes are involved in the early steps of carcinogenesis. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, Bristol-Myers Squibb/ImClone, Boehringer Ingelheim, Lilly, Merck Serono, OSI/Genentech/ Roche, Pfizer, Syndax AstraZeneca, Biogen Idec, Genentech, Genmab, Merck, OSI, Syndax, Ventana-Roche Abbott Laboratories
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 10575
Gene expression differences in current versus former smokers lung squamous preneoplasia.
10575 Background: The study of the molecular biology of the lung carcinogenesis would help finding biomarkers for early diagnosis and targets for chemoprevention. The present study aim to characterize genomic profiles between current and formers smokers in lung squamous carcinogenesis. Methods: 122 bronchial biopsies (67/55 from current/former smokers) at successive stages of lung squamous carcinogenesis (normal, hyperplasia, metaplasia, mild, moderate and severe dysplasia, carcinoma in situ and invasive carcinoma) obtained by fluorescence bronchoscopy in 74 high risk individuals (40/34 current/former smokers) were analyzed by gene expression microarrays (Mascaux, J Thorac Oncol 2009 4(9) S282). Results: 740 genes were significantly differentially expressed (FDR 0.05) between biopsies from current versus former smokers in bronchial pre-invasive lesions. The most significantly associated pathways was metabolism of xenobiotic by cytochrome CP450 eg CYP1A1, CYP2A6, ALDH1L1, but genes related to cancer pathways were also found, ie metallopeptidases, IGF binding proteins, cell growth and proliferation (ie EGF), or apoptosis (ie survivin). Our findings in lung preneoplasia were consistent by gene set enrichement analyses. (GSEA) with data previously reported on normal bronchial epithelial cells (Spira, PNAS 2004 101(27) 10143). Association between gene expression differences observed between the early steps of lung carcinogenesis in our study and between current and former smokers in normal bronchial epithelial cells in Spira study were analysed by GSEA. Some associations were observed: genes down-regulated in current smokers were also down-regulated in transition to squamous metaplasia including cancer genes like eg BCL2, FGF2, AKT3 and eicosanoid signaling eg PTGDR, PLA2G5. Conclusions: Genes discriminating current and former smokers during lung carcinogenesis include genes involved in metabolism of xenobiotic by cytochrome CP450, cell proliferation and apoptosis. Cigarette smoke exposure effects on normal epithelial cells and on preneoplasia from different data sets are related. Genes related to current smoking like eicosanoid signaling genes are involved in the early steps of carcinogenesis. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, Bristol-Myers Squibb/ImClone, Boehringer Ingelheim, Lilly, Merck Serono, OSI/Genentech/ Roche, Pfizer, Syndax AstraZeneca, Biogen Idec, Genentech, Genmab, Merck, OSI, Syndax, Ventana-Roche Abbott Laboratories
- 1 November 2008
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 25 (9) , 1164
Évolution de l’expression des microARNs au cours des étapes successives de la carcinogenèse épidermoïde bronchique
- 1 November 2008
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 25 (9) , 1164
Évolution de l’expression des microARNs au cours des étapes successives de la carcinogenèse épidermoïde bronchique
- 1 November 2008
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 25 (9) , 1164
Évolution de l’expression génique au cours de la carcinogenèse épidermoïde bronchique
- 1 November 2008
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 25 (9) , 1164
Évolution de l’expression génique au cours de la carcinogenèse épidermoïde bronchique
- 1 October 2008
- Vol. 25, 3S32-9
[Etiology, epidemiology, biology. Lung carcinogenesis].
Lung cancer is a complex disease involving various oncogenic pathways. Its early detection, at pre-invasive stages, could offer the opportunity of improving the bad prognosis of this cancer. Pre-invasive stages exist for different forms of lung cancer and some of them are recognized as being preneoplastic: dysplasias and in situ carcinoma, atypical adenomatous hyperplasia and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia are supposed to be precursors of squamous cell carcinomas, adenocarcinomas and carcinoid tumors, respectively. The sequence of histological modifications of bronchial mucosa preceding the development of a squamous cell carcinoma are well documented while those preceding other histological types are less known. This paper summarizes available data about histological modifications defining those preneoplastic and/or pre-invasive lesions, their principal clinical characteristics and the possibilities for their diagnosis. It also discusses arguments for their preneoplastic nature, their evolution and risk of progression risk, molecular abnormalities involved in lung carcinogenesis and clinical relevance of these lesions.
- 1 October 2008
- Vol. 25, 3S32-9
[Etiology, epidemiology, biology. Lung carcinogenesis].
Lung cancer is a complex disease involving various oncogenic pathways. Its early detection, at pre-invasive stages, could offer the opportunity of improving the bad prognosis of this cancer. Pre-invasive stages exist for different forms of lung cancer and some of them are recognized as being preneoplastic: dysplasias and in situ carcinoma, atypical adenomatous hyperplasia and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia are supposed to be precursors of squamous cell carcinomas, adenocarcinomas and carcinoid tumors, respectively. The sequence of histological modifications of bronchial mucosa preceding the development of a squamous cell carcinoma are well documented while those preceding other histological types are less known. This paper summarizes available data about histological modifications defining those preneoplastic and/or pre-invasive lesions, their principal clinical characteristics and the possibilities for their diagnosis. It also discusses arguments for their preneoplastic nature, their evolution and risk of progression risk, molecular abnormalities involved in lung carcinogenesis and clinical relevance of these lesions.
- Open Access
- 14 May 2008
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 32 (3) , 678-686
The role of NPM, p14arf and MDM2 in precursors of bronchial squamous cell carcinoma
Murine double minute clone 2 (MDM2), p14 alternate reading frame (p14arf), and nucleophosmin (NPM) regulate p53 activity.A total of 200 biopsies, including normal bronchial, pre-invasive and invasive tissues, were examined for changes in NPM, p14arf, MDM2 and p53 expression patterns by immunohistochemistry and immunofluorescence with confocal microscopy.NPM and p14arf displayed a diffuse nuclear staining in most normal bronchial tissue. The fraction of biopsies displaying an increased MDM2 staining or a nucleolar relocalisation of NPM increased at mild and moderate dysplasia, respectively. Two different modifications occurred in p14arf expression,i.e.its loss or its nucleolar relocalisation, both increasing at severe dysplasia and both being associated with high MDM2 expression. In addition, the nucleolar relocalisation of p14arf was associated with that of NPM. Immunofluorescence staining indicated that NPM and p14arf either co-localised in the nucleoplasm or in the nucleoli, before and as a result of severe dysplasia, respectively. MDM2 was not detected in the nucleoli.Thus, changes occur in murine double minute clone 2, p14 alternate reading frame and nucleophosmin level of expression and/or cellular distribution during early steps of lung carcinogenesis. Their relative localisation as determined by immunofluorescence, supports the hypothesis that p14 alternate reading frame nucleolar relocalisation impairs p14 alternate reading frame–murine double minute clone 2 complex formation and that nucleophosmin might sequester p14 alternate reading frame. The demonstration of this hypothesis requires further functional studies.
- 14 May 2008
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 32 (3) , 678-686
Open AccessThe role of NPM, p14arf and MDM2 in precursors of bronchial squamous cell carcinoma
Murine double minute clone 2 (MDM2), p14 alternate reading frame (p14arf), and nucleophosmin (NPM) regulate p53 activity.A total of 200 biopsies, including normal bronchial, pre-invasive and invasive tissues, were examined for changes in NPM, p14arf, MDM2 and p53 expression patterns by immunohistochemistry and immunofluorescence with confocal microscopy.NPM and p14arf displayed a diffuse nuclear staining in most normal bronchial tissue. The fraction of biopsies displaying an increased MDM2 staining or a nucleolar relocalisation of NPM increased at mild and moderate dysplasia, respectively. Two different modifications occurred in p14arf expression,i.e.its loss or its nucleolar relocalisation, both increasing at severe dysplasia and both being associated with high MDM2 expression. In addition, the nucleolar relocalisation of p14arf was associated with that of NPM. Immunofluorescence staining indicated that NPM and p14arf either co-localised in the nucleoplasm or in the nucleoli, before and as a result of severe dysplasia, respectively. MDM2 was not detected in the nucleoli.Thus, changes occur in murine double minute clone 2, p14 alternate reading frame and nucleophosmin level of expression and/or cellular distribution during early steps of lung carcinogenesis. Their relative localisation as determined by immunofluorescence, supports the hypothesis that p14 alternate reading frame nucleolar relocalisation impairs p14 alternate reading frame–murine double minute clone 2 complex formation and that nucleophosmin might sequester p14 alternate reading frame. The demonstration of this hypothesis requires further functional studies.
- 1 November 2006
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 23 (5) , 534
045 Expressions de 7 protéines impliquées dans les voies de l’apoptose au cours de la carcinogenèse bronchique épidermoïde
- 1 November 2006
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 23 (5) , 534
045 Expressions de 7 protéines impliquées dans les voies de l’apoptose au cours de la carcinogenèse bronchique épidermoïde
- Open Access
- 20 June 2006
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (2) , 139-145
Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results
Cyclooxygenase-2 (COX-2) is overexpressed in lung cancer, especially in adenocarcinoma (ADC). Our aim was to determine the prognostic value of COX-2 on survival in patients with lung cancer. Studies evaluating the survival impact of COX-2 in lung cancer, published until December 2005, were selected. Data for estimation of individual hazard ratios (HR) for survival were extracted from the publications and combined in a pooled HR. Among 14 eligible papers, all dealing with non-small-cell lung cancer, 10 provided results for meta-analysis of survival data (evaluable studies). Cyclooxygenase-2 positivity was associated with reduced survival, improved survival or no statistically significant impact in six, one and seven studies, respectively. Combined HR for the 10 evaluable studies (1236 patients) was 1.39 (95% confidence intervals (CI): 0.97–1.99). In stage I lung cancer (six evaluable studies, 554 patients), it was 1.64 (95% CI: 1.21–2.24). No significant impact was shown in ADC. A slight detrimental effect on survival in patients with lung cancer is associated with COX-2 expression, but the statistical significance is not reached. This effect is statistically significant in stage I, suggesting that COX-2 expression could be useful at early stages to distinguish those with a worse prognosis.
- 20 June 2006
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (2) , 139-145
Open AccessHas Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results
Cyclooxygenase-2 (COX-2) is overexpressed in lung cancer, especially in adenocarcinoma (ADC). Our aim was to determine the prognostic value of COX-2 on survival in patients with lung cancer. Studies evaluating the survival impact of COX-2 in lung cancer, published until December 2005, were selected. Data for estimation of individual hazard ratios (HR) for survival were extracted from the publications and combined in a pooled HR. Among 14 eligible papers, all dealing with non-small-cell lung cancer, 10 provided results for meta-analysis of survival data (evaluable studies). Cyclooxygenase-2 positivity was associated with reduced survival, improved survival or no statistically significant impact in six, one and seven studies, respectively. Combined HR for the 10 evaluable studies (1236 patients) was 1.39 (95% confidence intervals (CI): 0.97–1.99). In stage I lung cancer (six evaluable studies, 554 patients), it was 1.64 (95% CI: 1.21–2.24). No significant impact was shown in ADC. A slight detrimental effect on survival in patients with lung cancer is associated with COX-2 expression, but the statistical significance is not reached. This effect is statistically significant in stage I, suggesting that COX-2 expression could be useful at early stages to distinguish those with a worse prognosis.
- Open Access
- 25 April 2006
- Published by Springer Nature in British Journal of Cancer
- Vol. 94 (10) , 1549
Reply: K-Ras: a prognostic factor for survival in non-small cell lung cancer
- 25 April 2006
- Published by Springer Nature in British Journal of Cancer
- Vol. 94 (10) , 1549
Open AccessReply: K-Ras: a prognostic factor for survival in non-small cell lung cancer
- 30 November 2005
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 22 (5) , 873
058 Carcinogenèse bronchique précoce : expression de p14 et sa relation avec celle de p53 et de MDM2 dans les lésions prénéoplasiques bronchiques
- 30 November 2005
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 22 (5) , 873
058 Carcinogenèse bronchique précoce : expression de p14 et sa relation avec celle de p53 et de MDM2 dans les lésions prénéoplasiques bronchiques